The effect of desvenlafaxine on cognitive functioning in employed outpatients with major depressive disorder: a substudy of a randomized, double-blind, placebo-controlled trial
- 23 March 2016
- journal article
- research article
- Published by SAGE Publications in Journal of Psychopharmacology
- Vol. 30 (6), 559-567
- https://doi.org/10.1177/0269881116631649
Abstract
The objective of this substudy was to examine the effect of desvenlafaxine 50 mg/day compared with placebo on cognitive function in employed outpatients with major depressive disorder. A total of 11/55 (20%) study sites in a 12-week, randomized, double-blind, placebo-controlled trial administered cognitive assessments in memory, attention, and executive functioning domains using the cognitive drug research system. Changes from baseline were subjected to analysis of covariance with baseline levels as covariates, using last observation carried forward data. A significant improvement with desvenlafaxine 50 mg/day (n=52) compared with placebo (n=29) was observed on the quality of working memory composite measure (0.081 units (0.005, 0.156); P=0.0365) at last observation carried forward. Improvement from baseline on the speed of working memory composite was significant for desvenlafaxine (−226.6 msec (−316.7, −136.4); PP=0.0354); however, the treatment effect was not significant. No significant differences between groups were observed on composite measures for attention. Treatment of depression with desvenlafaxine 50 mg/day may improve aspects of cognitive functioning, including working memory. Clinical Trial Registry No.: Clinicaltrials.gov identifier: NCT00824291This publication has 50 references indexed in Scilit:
- Efficacy and Safety of Desvenlafaxine 50 mg/d for Prevention of Relapse in Major Depressive DisorderPublished by Physicians Postgraduate Press, Inc ,2013
- Severity of Depression and Magnitude of Productivity LossAnnals of Family Medicine, 2011
- Cognitive performance in relapsing remitting multiple sclerosis: A longitudinal study in daily practice using a brief computerized cognitive batteryBMC Neurology, 2011
- Discovery of 1-[2-(2,4-Dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): A Novel Multimodal Compound for the Treatment of Major Depressive DisorderJournal of Medicinal Chemistry, 2011
- Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: An 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studiesClinical Therapeutics, 2009
- Atomoxetine for the treatment of executive dysfunction in Parkinson's disease: A pilot open‐label studyMovement Disorders, 2008
- The safety and tolerability of duloxetine in depressed elderly patients with and without medical comorbidityInternational Journal of Clinical Practice, 2007
- Adrenergic pharmacology and cognition: Focus on the prefrontal cortexPharmacology & Therapeutics, 2007
- Practice effects on cognitive tasks: a major problem?The Lancet Neurology, 2002
- A New Depression Scale Designed to be Sensitive to ChangeThe British Journal of Psychiatry, 1979